drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Gene-modified autologous CD19-directed CAR T-cell therapy manufactured on the PrimeCAR platform (~3-day process) with high T-naive content; administered as a single IV infusion after lymphodepletion to target and kill CD19+ B-lineage leukemia cells via CAR-mediated TCR/co-stimulatory signaling, T-cell activation, cytokine release, and cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express a CD19-directed chimeric antigen receptor. CAR engagement of CD19 on B-lineage leukemia cells triggers CD3ΞΆ and co-stimulatory signaling, activating T cells to proliferate, release cytokines, and execute perforin/granzyme-mediated cytotoxicity, resulting in targeted depletion of CD19+ malignant (and normal) B cells after lymphodepletion and single IV infusion.
drug_name
MC-1-50
nct_id_drug_ref
NCT06641024